Nordic Nanovector Announces Focus on Advancing PARADIGME and Actions to Extend Cash Runway into 2021
Oslo, Norway, 1 April 2020 Nordic Nanovector ASA (OSE: NANO) today announces a number of initiatives to speed up recruitment into its pivotal Phase 2b PARADIGME trial with Betalutin® in advanced follicular lymphoma (FL) as well as to extend its cash runway into 2021. A webcast will take place on Thursday 2 April at 10:00 am CET. Details below. At the time of the Q4 results in February, the company noted that it would, under its new management, critically assess the current strategy and clinical trial operations. Following this assessment several key development decisions have been